𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systemic scleroderma and small cell carcinoma of the lung

✍ Scribed by Deba P. Sarma; Thomas G. Weilbaecher


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
266 KB
Volume
29
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

A 64‐year‐old man diagnosed to have systemic scleroderma for 1 year developed small‐cell carcinoma of the lung. Six additional cases obtained from the literature describing small‐cell carcinoma occurring in patients with scleroderma are reviewed.


πŸ“œ SIMILAR VOLUMES


Hemophagocytosis by small cell lung carc
✍ Yair Molad; Pinhas Stark; Miron Prokocimer; Henry Joshua; Jack Pinkhas; Dr. Yech πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 226 KB πŸ‘ 1 views
Treatment of small cell lung carcinoma i
✍ Esther Dajczman; Li Yi Fu; David Small; Norman Wolkove; Harvey Kreisman πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 625 KB

## BACKGROUND. The number of elderly people with small cell lung carcinoma (SCLC) is increasing and currently nearly 25% are older than 70 years. Elderly patients may not tolerate intensive therapy and, therefore, often do not receive such treatment. Additionally, age may be an independent predicto

Meningeal carcinomatosis in small cell c
✍ Oster, Martin W. ;Fetell, Michael πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 427 KB

## Abstract Small cell carcinoma of the lung is extremely sensitive to chemotherapy and radiation therapy. We describe the case of a patient who had a complete response to such treatment but relapsed with meningeal carcinomatosis. We propose that prophylactic therapy to the spinal cord as well as t

Combination radiotherapy and chemotherap
✍ Goldberg, R. S. ;Joss, R. A. ;Bedwinek, J. ;Yates, J. W. ;Krakoff, I. H. πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 319 KB

Twenty previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide, 400 mg/m2 and Adriamycin, 40 mg/m2 IV on day 1, followed by cytosine arabinoside, 20 mg/m2, every 12 hours subcutaneously on days 5--9; this regimen was repeated every 28 days. On days 14--